- Home
- ALLO
as 04-25-2025 4:00pm EST
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 338.9M | IPO Year: | 2018 |
| Target Price: | $9.66 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.23 - $3.78 | Next Earning Date: | 05-12-2025 |
| Revenue: | $22,000 | Revenue Growth: | -76.84% |
| Revenue Growth (this year): | -30.45% | Revenue Growth (next year): | 9.07% |
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Yoshiyama Annie | ALLO | SVP, Finance | Apr 21 '25 | Sell | $1.41 | 9,601 | $13,537.41 | 130,663 | |
| Chang David D | ALLO | President and CEO | Mar 14 '25 | Sell | $1.96 | 46,668 | $91,469.28 | 5,276,569 | |
| Beneski Benjamin Machinas | ALLO | SVP, Chief Technical Officer | Mar 14 '25 | Sell | $1.98 | 5,488 | $10,838.80 | 218,507 | |
| MESSEMER DEBORAH M. | ALLO | Director | Feb 18 '25 | Sell | $2.43 | 13,313 | $32,350.59 | 144,316 | |
| Douglas Earl Martin | ALLO | SVP, General Counsel | Feb 3 '25 | Sell | $1.71 | 6,404 | $10,950.84 | 587,848 | |
| Parker Geoffrey M. | ALLO | CHIEF FINANCIAL OFFICER | Feb 3 '25 | Sell | $1.73 | 4,361 | $7,544.53 | 1,301,540 | |
| Chang David D | ALLO | President and CEO | Feb 3 '25 | Sell | $1.68 | 46,003 | $77,285.04 | 5,276,569 | |
| MOORE TIMOTHY L. | ALLO | Chief Technical Officer | Feb 3 '25 | Sell | $1.71 | 14,746 | $25,215.66 | 250,713 | |
| Roberts Zachary | ALLO | EVP of R&D | Feb 3 '25 | Sell | $1.70 | 18,832 | $32,014.40 | 643,135 |
Latest Allogene Therapeutics Inc. News
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst institutional investors who own 59%
GlobeNewswire
3 days ago
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Zacks
18 days ago
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
MT Newswires
19 days ago
Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases
GlobeNewswire
19 days ago
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
Simply Wall St.
a month ago
Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
a month ago
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ...
Zacks
a month ago
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
Compare ALLO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.